Zhengye Corp (ZYBT) Operating Margin

Corporate company logo of Zhengye Corp (ZYBT)

Zhengye Biotechnology (ZYBT) is actively developing its pipeline of biological products to combat zoonotic viruses. The operating income margin demonstrates the business's sensitivity to costs, where -59.20 captures the current state of the parameter. The company's eco-friendly approach reduces the use of antibiotics in livestock farming. Stability is ensured by strict adherence to biosafety protocols and the engagement of specialized immunologists to create vaccines.

Zhengye Biotechnology Co., Ltd. (ZYBT): Return on Sales by Operating Profit from 01/08/2025 to 11/20/2026

Comprehensive metric breakdowns and analytics for jlzybio.com (ZYBT)

- share price and consensus valuation forecast:
Fundamental company analysis:Jilin Zhengye Biotechnology, ZYBT
Core merchandise of Zhengye Biotechnology

For Zhengye Biotechnology (ZYBT), which specializes in veterinary vaccines, the operating margin determines the production efficiency of livestock pharmaceuticals. This metric is calculated as the ratio of operating profit to total revenue, excluding the impact of taxes and debt service. The recorded operating margin demonstrates the business's ability to generate cash flow from core sales. A compression of this indicator signals rising raw material costs, while a stable level confirms the company's high competitiveness in the Asian market.